Does differing metabolism by cytochrome p450 have clinical importance?

被引:46
作者
Davidson M.H. [1 ]
机构
[1] Chicago Center for Clinical Research, 515 North State Street, Chicago, 60610, Illinois
关键词
Statin; Simvastatin; Atorvastatin; Pravastatin; Lovastatin;
D O I
10.1007/s11883-000-0090-4
中图分类号
学科分类号
摘要
The cytochrome P450 (CYP) is a group of enzymes that oxidatively modify drugs to a more water-soluble form for renal excretion. Nearly 50% of all clinically used medications and endogenous steroids are metabolized by the CYP enzyme 3A4, which explains why many of the important potential drug interactions involved this enzyme. Despite an excellent safety record, CYP 3A4 statins (lovastatin, simvastatin, atorvastatin) taken concomitantly with a potent CYP 3A4 inhibitor may increase the risk for adverse events (myopathy, rhabdomyolysis). This article describes the clinical significance of CYP metabolism as the pathways relate to the use of statins, including brief discussions on statins, fibrates, cyclosporine, and calcium channel blockers. In light of these potential interactions, continued vigilance by physicians is necessary to ensure the safe use of statins.
引用
收藏
页码:14 / 19
页数:5
相关论文
共 90 条
[1]  
Slaughter RL(1995)Recent advances: the cytochrome P450 enzymes Ann Pharmacother 29 619-624
[2]  
Edwards DJ(1997)Mibefradil—a new calcium channel blocker Med Lett Drug Ther 39 103-105
[3]  
Abramowicz M(1998)The interaction of diltiazem with lovastatin and pravastatin Clin Pharmacol Ther 64 369-377
[4]  
Agbin NE(1999)Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy Am J Cardiol 83 1146-1146
[5]  
Brater C(1996)Efficacy and tolerabil-ity of low-dose simvastatin and niacin, alone and in combi-nation, in patients with combined hyperlipidemia: a pro-spective trial J Cardiovasc Pharmacol Therapeut 1 107-116
[6]  
Becker PA(1994)Comparative efficacy and safety of pravastatin, nicotinic acid, and the two com-bined in patients with hypercholesterolemia Am J Cardiol 73 339-339
[7]  
Pogson GW(1988)Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients JAMA 260 239-241
[8]  
Kindred LH(1988)Lovastatin and rhabdomyolysis [letter] Ann Intern Med 109 682-683
[9]  
Carper BG(1993)Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients Transplant Proc 25 2732-2734
[10]  
Stein EA(1997)Accumulation of lovastatin, but not pravastatin, in blood of cyclosporine-treated kidney graft patients after multiple doses Clin Pharmacol Ther 62 311-321